2023年5月11日,

北卡罗来纳州研究三角园- 5月11日,2023 - Asklepios生物制药,Inc . (AskBio),基因疗法公司全资和拜耳公司的子公司独立运营,将11演示提供洞察腺相关病毒(AAV)的研究和开发治疗一系列的疾病基因和细胞治疗的美国社会(ASGCT) 26日年会发生5月16 - 20,2023年,在洛杉矶,美国。AskBio演讲涵盖临床前研究免疫反应AAV数据方法来改善AAV-gene功效的治疗和改善分析和生物分析的研究。研讨会上一个平台方法AAV制造业也将呈现Viralgen AskBio的子公司。“我们的科学存在ASGCT反映了前沿的类型我们的团队进行临床前研究,我们认为是至关重要的成功发展的基因疗法在未来,“Jude Samulski说,首席科学官和AskBio创始人之一。“我们期待展示更新的开创性工作横跨AAV载体设计的精妙之处,可量化的转基因表达和临床疗效,目的是进一步发展AAV治疗额外的未满足的临床需求。“雄心勃勃的投资组合的基因疗法在研究和发展的不同阶段,AskBio继续发展AAV-based疗法治疗的一些世界上最使人衰弱的疾病,包括充血性心力衰竭、亨廷顿氏舞蹈症,肢带肌萎缩症,多系统萎缩,帕金森病,和筛疾病。通过针对这些治疗领域,AskBio旨在提供突破性的治疗,全世界有超过3500万的患者受益。1 - 7 AskBio ASGCT的报告包括:关于AskBio Asklepios生物制药,Inc . (AskBio)全资和拜耳公司的独立运营的子公司, 是一个完全集成的基因疗法公司致力于开发救命药物和改变生活。临床项目公司维护一个组合的一系列神经肌肉,中枢神经系统,心血管和代谢疾病适应症的临床分期管道包括充血性心力衰竭的治疗,亨廷顿氏舞蹈症,肢带肌萎缩症,多系统萎缩,帕金森病,疾病筛。 AskBio’s gene therapy platform includes Pro10™, an industry-leading proprietary cell line manufacturing process, and an extensive capsid and promoter library. With global headquarters in Research Triangle Park, North Carolina, and European headquarters in Edinburgh, Scotland, the company has generated hundreds of proprietary capsids and promoters, several of which have entered clinical testing. An early innovator in the gene therapy field, with over 800 employees in five countries, the company holds more than 750 patents in areas such as AAV production and chimeric and self-complementary capsids. Learn more at www.askbio.com or follow us on LinkedIn. About Viralgen Viralgen, an independently operated Contract Development and Manufacturing Organization (CDMO), was founded in 2017 as a joint venture between AskBio and Columbus Venture Partners (a venture capital firm based in Spain). As one of the world’s leading manufacturers of cGMP-certified AAV, Viralgen uses the Pro10TM based suspension manufacturing platform, a technology licensed from AskBio and developed by CTO Josh Grieger and co-founder R. Jude Samulski, PhD, at University of North Carolina. It is believed that ...读新闻